Target chemotherapy of anti-CD147 antibody-labeled liposome encapsulated GSH-DXR conjugate on CD147 highly expressed carcinoma cells

Abstract

Abstract. It was confirmed that CD147 (Emmprin) was expressed on the cell surface of carcinoma cells. For the purpose of studying the efficacy of a CD147-targeting agent on CD147-expressing carcinoma cells, we investigated the effect of a conjugate of glutathione-doxorubicin (GSH-DXR) encapsulated in an anti-CD147 antibody-labeled liposome (aCD147ab-liposome) in terms of specific accumulation and cytotoxicity in CD147-expressing human carcinoma cells. Expression of CD147 was not observed in many normal human tissues. However, slight expression of CD147 in kidney, prostate and breast tissues was observed. By contrast, high-level expression of CD147 in all carcinoma cells such as A431, PC3 and Ishikawa cell lines was confirmed by fluorescent microscopy and Western blot analysis. Specific accumulation of the aCD147ab-liposome in the abovedescribed CD147-expressing cells was observed. GSH-DXR encapsulated in an aCD147ab-liposome expressed specific cytotoxicity against these carcinoma cells. These results suggested that target chemotherapy of GSH-DXR encapsulated in an aCD147ab-liposome on CD147-expressing carcinoma cells was effective.

Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression

“…Recently, Dean et al [43] demonstrated treatment with anti-CD147 MAb delayed tumor growth in a mouse model of head and neck cancer compared with untreated controls and increased sensitivity of radiation therapy. Using a conjugate of glutathione-doxorubicin (GSH-DXR) encapsulated in an anti-CD147 antibodylabeled liposome (aCD147ab-liposome), Matsudaira et al [44] recently demonstrated that this target chemotherapy conjugate can effectively target CD147-positive cancer cells in vitro. An anti-tumor potential of MCT1 inhibition was most recently supported by a reduction of tumor growth in in vivo models of lung carcinoma, colorectal carcinoma and a squamous carcinoma cell line after acyano-4-hydroxycinnamate-mediated MCT1 inhibition [45].…”

Baculovirus display of single chain antibody (scFv) using a novel signal peptide

“…The ligand of scFv-M6-1B9 is M6, also called CD147 [38,39], a transmembrane glycoprotein highly expressed in various types of malignant cells [57] and tumors, e.g. nasopharyngeal carcinoma [58].…”

Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor

“…Considerable efforts have been expended on this approach; the most popular ligands are monoclonal antibodies or Fab fragments specific to tumor cell antigens [94-96], peptide [97], folate [98], and transferrin [99,100]. Most of these ligands are internalized by the clathrin-mediated endocytosis and are therefore subjected to the same considerations and limitations (see below).…”